NOV 17, 202655 MINS READ
Creatine phosphate (N-[aminoiminomethyl]-N-methylglycine phosphate, CAS 67-07-2) functions as the primary cellular energy buffer in vertebrate muscle and neural tissues, reversibly donating its phosphoryl group to adenosine diphosphate (ADP) via the creatine kinase (CK) reaction to regenerate adenosine triphosphate (ATP)15. The compound exists predominantly as a zwitterionic species at physiological pH (pKa ~4.5 for the phosphate group), with molecular weight 211.04 g/mol in its anhydrous form and 327.18 g/mol as the disodium salt tetrahydrate commonly used in pharmaceutical preparations89.
The phosphoramidate bond (P-N) in creatine phosphate exhibits a standard free energy of hydrolysis (ΔG°') of approximately -43.1 kJ/mol, positioning it above ATP (-30.5 kJ/mol) in the cellular energy hierarchy110. This thermodynamic property enables efficient ATP regeneration during periods of high metabolic demand, such as intense muscular contraction or neuronal firing. Structural analogs including cyclocreatine and phosphocreatine prodrugs have been synthesized to enhance membrane permeability and bioavailability, with modifications at the guanidino or carboxyl moieties234.
Key physicochemical properties relevant to wholesale handling include:
Understanding these molecular characteristics is essential for designing robust synthesis, purification, and formulation strategies that preserve compound integrity throughout the supply chain.
The enzymatic synthesis of creatine phosphate leverages the reversibility of the creatine kinase reaction, offering high regio- and stereoselectivity unattainable via purely chemical methods1. The classical approach involves incubating creatine with 3-phosphoglyceric acid (3-PGA) as phosphate donor in the presence of aqueous muscle extract (containing endogenous CK, phosphoglycerate kinase, and adenylate kinase) and a catalytic quantity of ATP (typically 0.1–1.0 mM)1. The reaction proceeds optimally at pH 9.0–10.5 (maintained via NaOH or KOH addition), 25–37°C, with molar ratios of creatine:3-PGA:ATP of approximately 1:1.2:0.011.
Critical process parameters include:
A significant advantage of enzymatic synthesis is the elimination of toxic reagents such as phosphoryl chloride (POCl₃), reducing environmental burden and simplifying downstream purification17. However, the requirement for expensive ATP and purified enzymes limits cost-competitiveness for bulk production, making this route more suitable for high-purity pharmaceutical-grade material or research quantities1.
Chemical synthesis of creatine phosphate traditionally employs phosphoryl chloride (POCl₃) or phosphorus pentoxide (P₂O₅) as phosphorylating agents, reacting with creatine or protected creatine derivatives under anhydrous conditions712. The reaction of creatine with POCl₃ in anhydrous pyridine at -10 to 0°C yields creatine phosphate via nucleophilic attack of the guanidino nitrogen on the electrophilic phosphorus center12:
Creatine + POCl₃ → Creatine-PO₃Cl₂ (intermediate) → Creatine Phosphate + HCl
Key challenges include:
An improved protocol involves pre-forming protected creatinol sulfate by reacting creatinol with sulfuric acid, followed by phosphorylation with POCl₃, ClPO₃H₂, or P₂O₅ at 50–70°C12. This approach achieves 60–85% yield with >99% purity after recrystallization from water-ethanol mixtures12. The overall reaction sequence is:
Creatinol + H₂SO₄ → Protected Creatinol Sulfate
Protected Creatinol Sulfate + POCl₃ → Creatinol O-Phosphate + HCl + H₂SO₄
Post-reaction workup involves neutralization with sodium hydroxide to pH 6.5–7.0, precipitation of the disodium salt, and washing with cold ethanol or butanone to remove colored impurities812. Final recrystallization from hot water (50–70°C) followed by vacuum filtration yields pharmaceutical-grade creatine phosphate with purity 99.05–99.8% as determined by HPLC12.
For wholesale production (>100 kg batches), chemical synthesis via POCl₃ remains the dominant route due to lower reagent costs ($2–5/kg creatine phosphate vs. $15–30/kg for enzymatic routes) and established infrastructure712. However, enzymatic methods are gaining traction for specialty applications requiring ultra-high purity (>99.5%) or specific isotopic labeling (e.g., ¹⁵N, ¹³C-enriched material for metabolic studies)1. Hybrid approaches combining enzymatic synthesis with chemical purification (e.g., ion-exchange chromatography on strongly anionic resins) offer a compromise, achieving 95–98% purity at intermediate cost8.
The isolation of creatine phosphate ions from crude reaction mixtures employs strongly anionic resins (e.g., Dowex 1×8, Amberlite IRA-400 in Cl⁻ or OH⁻ form) to selectively bind the negatively charged phosphate moiety while allowing neutral creatine and cationic impurities to elute8. The process involves:
This method achieves >95% recovery with purity 92–97%, suitable for further crystallization8. For analytical-scale purification, HPLC on anion-exchange columns (e.g., Dionex CarboPac PA1) with isocratic 50 mM NaOH elution provides baseline separation of creatine phosphate from creatine, inorganic phosphate, and ATP in <15 minutes18.
The final purification step exploits the differential solubility of creatine phosphate salts in aqueous-organic solvent systems712. A representative protocol for the disodium salt tetrahydrate involves:
This procedure yields creatine phosphate with purity 99.05–99.8% (HPLC), residual water content <0.5% (Karl Fischer titration), and endotoxin levels <0.5 EU/mg (LAL assay)12. For the calcium salt (used in certain injectable formulations), precipitation from aqueous solution at pH 6.5–7.0 with CaCl₂ followed by recrystallization from water-ethanol (3:1 v/v) affords material with melting point 243–244°C and purity >99%812.
Wholesale creatine phosphate must meet stringent pharmacopeial standards (USP, EP, JP) encompassing:
Advanced techniques such as capillary electrophoresis (CE) and ion chromatography (IC) provide orthogonal purity assessment, resolving closely related phosphorylated metabolites (ADP, AMP, pyrophosphate) that may co-elute in HPLC18.
Creatine phosphate intended for injectable or oral pharmaceutical formulations must comply with Good Manufacturing Practice (GMP) regulations (FDA 21 CFR Part 211, EMA EudraLex Volume 4) and be sourced from facilities holding Drug Master Files (DMF) or Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM)71314. Key regulatory requirements include:
Pharmaceutical preparations combining creatine phosphate with creatine phosphokinase (creatine kinase) for enhanced bioavailability have been described, requiring additional enzyme activity assays (U/mg protein) and sterility testing for parenteral formulations1314.
Creatine phosphate marketed as a dietary supplement falls under less stringent regulations (FDA DSHEA, EU Regulation 1924/2006) but must adhere to Good Manufacturing Practice for dietary supplements (21 CFR Part 111) and carry appropriate labeling disclaimers5615. Key considerations include:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| BOEHRINGER MANNHEIM GMBH | Pharmaceutical-grade creatine phosphate manufacturing for injectable formulations and high-purity research applications requiring >99% purity and compliance with GMP standards. | Enzymatic Creatine Phosphate Production System | Achieves 60-85% isolated yield through enzymatic phosphorylation using muscle extract with creatine kinase, eliminating toxic phosphoryl chloride and simplifying downstream purification compared to chemical synthesis routes. |
| XENOPORT INC. | Therapeutic interventions for ischemia, heart failure, neurodegenerative disorders, and cardiovascular conditions requiring rapid intracellular energy restoration. | Membrane Permeable Creatine Phosphate Prodrugs | Enhanced membrane permeability and bioavailability through structural modifications at guanidino or carboxyl moieties, enabling efficient cellular uptake and ATP regeneration in energy-deficient tissues. |
| BASF AKTIENGESELLSCHAFT | Sports nutrition supplements and pharmaceutical formulations requiring high-purity creatine (>99%) with optimal handling properties for bulk distribution and consumer applications. | High-Purity Creatine Purification Process | Produces creatine monohydrate crystals with reduced fines content and coarser particle size through controlled dissolution and recrystallization, minimizing dust formation and electrostatic charging while achieving pharmaceutical-grade purity. |
| TIANJIN TIANCHENG PHARMACEUTICAL CO. LTD. | Industrial-scale production of creatinol O-phosphate for cardiovascular and neuromuscular therapeutic applications requiring stringent quality control and regulatory compliance. | Creatinol O-Phosphate Chemical Synthesis | Achieves 60-85% yield and 99.05% purity through protected creatinol sulfate intermediate pathway using POCl3, with melting point 243-244°C verified by HPLC analysis and re-crystallization protocols. |
| STAB. CHIMICI FARM. RIUN. SCHIAPPARELLI | Pharmaceutical preparations for parenteral administration in cardiac surgery pre-treatment, angina therapy, and acute energy metabolism support in clinical settings. | Calcium Salt Creatine Phosphate Purification | Isolates creatine phosphate ions via strongly anionic resin chromatography followed by calcium salt precipitation, achieving high purity suitable for therapeutic injectable formulations with controlled impurity profiles. |